Conversion to sirolimus immunosuppression in liver transplantation recipients with hepatocellular carcinoma: Report of an initial experience.

摘要: AIM: To report a retrospective analysis of preliminary results 36 patients who received sirolimus (SRL, Rapamune®, rapamycin) in consecutive cohort 248 liver allograft recipients. METHODS: Thirty-six transplant with hepatocellular carcinoma (HCC) were switched to SRL-based immunosuppression therapy from tacrolimus enrolled this study. The diagnosed as advanced HCC before orthotopic transplantation (OLT) divided into group A (n = 11), those found have recurrence and/or metastasis after OLT assigned B 18), and developed renal insufficiency caused by calcineurin inhibitor (CNI) C 7) OLT. RESULTS: followed up for median 10.4 mo (range, 3.8-19.1 mo) conversion SRL 12.3 5.1-34.4 OLT. Three mild acute cellular rejection 2 wk initiating therapy, which was fully reversed prednisolone pulse therapy. In A, only 1 patient 12 B, 66.7% (12/18) (2 progressive tumor, 7 stable tumor 3 without tumor) still alive due conversing resection at the end follow-up 6.8 post 10.7 posttransplant. C, no demonstrated patients, function became normal Thrombocytopenia 2), anemia 8), oral aphthous ulcers our easily manageable. CONCLUSION: may inhibit improve CNI-induced HCC.